117 related articles for article (PubMed ID: 6469399)
1. Vinblastine and vincristine--growth-inhibitory effects correlate with their retention by cultured Nb 2 node lymphoma cells.
Gout PW; Noble RL; Bruchovsky N; Beer CT
Int J Cancer; 1984 Aug; 34(2):245-8. PubMed ID: 6469399
[TBL] [Abstract][Full Text] [Related]
2. Accumulation and release of vinblastine and vincristine by HeLa cells: light microscopic, cinematographic, and biochemical study.
Lengsfeld AM; Dietrich J; Schultze-Maurer B
Cancer Res; 1982 Sep; 42(9):3798-805. PubMed ID: 7105045
[TBL] [Abstract][Full Text] [Related]
3. Factors governing the modulation of vinca-alkaloid resistance in doxorubicin-resistant cells by the calmodulin inhibitor trifluoperazine.
Ganapathi R; Grabowski D; Schmidt H
Biochem Pharmacol; 1986 Feb; 35(4):673-8. PubMed ID: 3947398
[TBL] [Abstract][Full Text] [Related]
4. Use of snail neurons in developing quantitative ultrastructural parameters for neurotoxic side effects of Vinca antitumor agents.
Müller LJ; Moorer-van Delft CM; Zijl R; Roubos EW
Cancer Res; 1990 Mar; 50(6):1924-8. PubMed ID: 2407348
[TBL] [Abstract][Full Text] [Related]
5. Determinants of intrinsic sensitivity to Vinca alkaloids in xenografts of pediatric rhabdomyosarcomas.
Houghton JA; Williams LG; Torrance PM; Houghton PJ
Cancer Res; 1984 Feb; 44(2):582-90. PubMed ID: 6692363
[TBL] [Abstract][Full Text] [Related]
6. Structural determinants of phenoxazine type compounds required to modulate the accumulation of vinblastine and vincristine in multidrug-resistant cell lines.
Thimmaiah KN; Horton JK; Qian XD; Beck WT; Houghton JA; Houghton PJ
Cancer Commun; 1990; 2(7):249-59. PubMed ID: 2378785
[TBL] [Abstract][Full Text] [Related]
7. Relationship between the cellular accumulation and the cytotoxicity of S12363, a new Vinca alkaloid derivative.
Pierré A; Pérez V; Léonce S; Boutin JA; Saint-Dizier D; Hautefaye P; Lavielle G; Atassi G
Cancer Chemother Pharmacol; 1992; 29(5):367-74. PubMed ID: 1551175
[TBL] [Abstract][Full Text] [Related]
8. The distribution of [3H]vinblastine in tumor and host tissues of Nb rats bearting a transplantable lymphoma which is highly sensitive to the alkaloid.
Noble RL; Gout PW; Wijcik LL; Hebden HF; Beer CT
Cancer Res; 1977 May; 37(5):1455-60. PubMed ID: 856464
[TBL] [Abstract][Full Text] [Related]
9. NMR and mass spectrometric characterization of vinblastine, vincristine and some new related impurities--part II.
Háda V; Dubrovay Z; Lakó-Futó A; Galambos J; Gulyás Z; Aranyi A; Szántay C
J Pharm Biomed Anal; 2013 Oct; 84():309-22. PubMed ID: 23177164
[TBL] [Abstract][Full Text] [Related]
10. Differential cellular retention of vincristine and vinblastine by cultured human promyelocytic leukemia HL-60/Cl cells: the basis of differential toxicity.
Ferguson PJ; Cass CE
Cancer Res; 1985 Nov; 45(11 Pt 1):5480-8. PubMed ID: 3863705
[TBL] [Abstract][Full Text] [Related]
11. Studies with 4'-deoxyepivincristine (vinepidine), a semisynthetic vinca alkaloid.
Mullin K; Houghton PJ; Houghton JA; Horowitz ME
Biochem Pharmacol; 1985 Jun; 34(11):1975-9. PubMed ID: 4004913
[TBL] [Abstract][Full Text] [Related]
12. NMR and mass spectrometric characterization of vinblastine, vincristine and some new related impurities - part I.
Dubrovay Z; Háda V; Béni Z; Szántay C
J Pharm Biomed Anal; 2013 Oct; 84():293-308. PubMed ID: 22985529
[TBL] [Abstract][Full Text] [Related]
13. Uptake of Vinca alkaloids into mammalian nerve and its subcellular components.
Iqbal Z; Ochs S
J Neurochem; 1980 Jan; 34(1):59-68. PubMed ID: 6161213
[TBL] [Abstract][Full Text] [Related]
14. In vivo and in vitro pharmacokinetics and metabolism of vincaalkaloids in rat. II. Vinblastine and vincristine.
Zhou XJ; Martin M; Placidi M; Cano JP; Rahmani R
Eur J Drug Metab Pharmacokinet; 1990; 15(4):323-32. PubMed ID: 2088769
[TBL] [Abstract][Full Text] [Related]
15. Block of axoplasmic transport in vitro by vinca alkaloids.
Chan SY; Worth R; Ochs S
J Neurobiol; 1980 May; 11(3):251-64. PubMed ID: 6156229
[TBL] [Abstract][Full Text] [Related]
16. Energy-dependent reduced drug binding as a mechanism of Vinca alkaloid resistance in human leukemic lymphoblasts.
Beck WT; Cirtain MC; Lefko JL
Mol Pharmacol; 1983 Nov; 24(3):485-92. PubMed ID: 6579344
[TBL] [Abstract][Full Text] [Related]
17. Comparative uptake, retention and action of vincristine, vinblastine and vindesine on murine leukaemic lymphoblasts sensitive and resistant to vincristine.
Rivera-Fillat MP; Pallarés-Trujillo J; Domènech C; Grau-Oliete MR
Br J Pharmacol; 1988 Apr; 93(4):902-8. PubMed ID: 3390658
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the interaction of TZT-1027, a potent antitumor agent, with tubulin.
Natsume T; Watanabe J; Tamaoki S; Fujio N; Miyasaka K; Kobayashi M
Jpn J Cancer Res; 2000 Jul; 91(7):737-47. PubMed ID: 10920282
[TBL] [Abstract][Full Text] [Related]
19. Differential activity of vincristine and vinblastine against cultured cells.
Ferguson PJ; Phillips JR; Selner M; Cass CE
Cancer Res; 1984 Aug; 44(8):3307-12. PubMed ID: 6744266
[TBL] [Abstract][Full Text] [Related]
20. Relationship between binding affinity, retention and sensitivity of human rhabdomyosarcoma xenografts to Vinca alkaloids.
Houghton JA; Williams LG; Dodge RK; George SL; Hazelton BJ; Houghton PJ
Biochem Pharmacol; 1987 Jan; 36(1):81-8. PubMed ID: 3541941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
